| Bausch and Lomb acquires Tubilux assets | Posted on 09/10/2009 in Pharmacy Supplier News Bausch and Lomb revealed this week that it has acquired the commercial assets from the Italian ophthalmic pharmaceuticals organisation Tubilux.
Tubilux is a privately-held company that develops and markets various over-the-counter branded and generic pharmaceutical products and distributes its items in around 30 countries.
Its ophthalmic pharmaceuticals portfolio and commercial and sales operations will be owned by Bausch and Lomb, but Tubilux is set to retain its manufacturing venture, producing existing products under a multi-year agreement.
Charl van Zyl, head of the pharmaceuticals business for Europe, the Middle East and Africa, stated: "Bausch and Lomb is committed to expanding our portfolio offerings and we believe that this investment will prove successful for the company, doctors and patients alike."
In September, Bausch and Lomb announced that it had appointed two new directors to its board - Kerry Clark and Robert Palmisano.
Mr Clark served Procter and Gamble for more than 30 years, while his colleague is currently the president, chief executive and director of ev3.
Other news stories from 09/10/2009
Read more in the Zenopa News Archive
How this news is generated
|  |
|
